136 related articles for article (PubMed ID: 36510033)
21. Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models.
Wang D; Lu J; Li Q; Li Z
Exp Ther Med; 2019 May; 17(5):4023-4031. PubMed ID: 31007740
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children.
Sarashina A; Tatami S; Yamamura N; Tsuda Y; Igarashi T
Br J Clin Pharmacol; 2005 Jan; 59(1):43-53. PubMed ID: 15606439
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome
.
Wang X; Han Y; Chen C; Ma L; Xiao H; Zhou Y; Cui Y; Wang F; Su B; Yao Y; Ding J
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):125-134. PubMed ID: 30663980
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.
Zang YN; Dong F; Li AN; Wang CY; Guo GX; Wang Q; Zhang YF; Zhang L; de Leon J; Ruan CJ
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):353-371. PubMed ID: 33677821
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
[TBL] [Abstract][Full Text] [Related]
28. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition.
Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB
Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994
[TBL] [Abstract][Full Text] [Related]
29. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
[TBL] [Abstract][Full Text] [Related]
30. [Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].
Zhang S; Wang L; Lu W
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):105-9. PubMed ID: 18433522
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics and dose simulation of cyclosporine in Chinese children with nephrotic syndrome: Effects of weight and total cholesterol.
Zhao Y; He H; Zang Y; Zhao L; Wang X
Int J Clin Pharmacol Ther; 2022 Feb; 60(2):87-96. PubMed ID: 34753558
[TBL] [Abstract][Full Text] [Related]
32. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B; Aghai-Trommeschlaeger F; Kraus S; Grigoleit GU; Zimmermann S; Kurlbaum M; Klinker H; Isberner N; Scherf-Clavel O
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559050
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation.
Wei Y; Wu D; Chen Y; Dong C; Qi J; Wu Y; Cai R; Zhou S; Li C; Niu L; Wu T; Xiao Y; Liu T
Front Pharmacol; 2022; 13():1002628. PubMed ID: 36313303
[No Abstract] [Full Text] [Related]
34. Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of
Shen X; Chen X; Lu J; Chen Q; Li W; Zhu J; He Y; Guo H; Xu C; Fan X
Front Pharmacol; 2022; 13():1037239. PubMed ID: 36506519
[No Abstract] [Full Text] [Related]
35. Population Pharmacokinetics and Individualized Medication of Azithromycin for Injection in Children Under 6 Years Old.
Zhang Y; Wang Y; Li J; Wang H; Hou M; Dong R; Li X
J Pharm Sci; 2024 May; 113(5):1351-1358. PubMed ID: 38253224
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder.
Zang YN; Guo W; Niu MX; Bao S; Wang Q; Wang Y; Dong F; Li AN; Ruan CJ
Eur J Clin Pharmacol; 2022 Mar; 78(3):405-418. PubMed ID: 34854947
[TBL] [Abstract][Full Text] [Related]
37. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of valproate in Chinese children with epilepsy.
Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
[TBL] [Abstract][Full Text] [Related]
39. Outcome analysis of pediatric hemophagocytic lymphohistiocytosis.
Chen TY; Hsu MH; Kuo HC; Sheen JM; Cheng MC; Lin YJ
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):172-179. PubMed ID: 32307323
[TBL] [Abstract][Full Text] [Related]
40. Impact of Donor and Recipient
Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
